<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Ann Lab Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Ann Lab Med</journal-id>
      <journal-id journal-id-type="publisher-id">ALM</journal-id>
      <journal-title-group>
        <journal-title>Annals of Laboratory Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2234-3806</issn>
      <issn pub-type="epub">2234-3814</issn>
      <publisher>
        <publisher-name>The Korean Society for Laboratory Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25729731</article-id>
      <article-id pub-id-type="pmc">4330179</article-id>
      <article-id pub-id-type="doi">10.3343/alm.2015.35.2.254</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
          <subj-group subj-group-type="heading">
            <subject>Diagnostic Hematology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pediatric B-cell Lymphoma, Unclassifiable, With Intermediate Features Between Those of Diffuse Large B-cell Lymphoma and Burkitt Lymphoma: A Report of Two Cases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Zhang</surname>
            <given-names>Shanxiang</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wilson</surname>
            <given-names>David</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Czader</surname>
            <given-names>Magdalena</given-names>
          </name>
          <degrees>M.D.</degrees>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Pathology and Laboratory Medicine, Indiana University, IN, USA.</aff>
      <aff id="A2"><label>2</label>AmeriPath, Indianapolis, IN, USA.</aff>
      <author-notes>
        <corresp>Corresponding author: Shanxiang Zhang. Department of Pathology and Laboratory Medicine, Indiana University, 350 West 11th Street, Room 5042, Indianapolis, IN 46202, USA. Tel: +1-317-491-6175, Fax: +1-317-491-6114, <email>sz5@iupui.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>2</month>
        <year>2015</year>
      </pub-date>
      <volume>35</volume>
      <issue>2</issue>
      <fpage>254</fpage>
      <lpage>256</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>1</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>15</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>11</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Korean Society for Laboratory Medicine.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>B-cell lymphoma, unclassifiable, with intermediate features between those of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL; intermediate BL/DLBCL) commonly exhibits a morphology similar to that of typical BL and an atypical immunophenotype such as diffuse and moderate-to-strong BCL2 positivity and/or a Ki67 proliferation index &lt;90%. Alternatively, the tumor cells exhibit greater variations in nuclear size and contouring than would be considered acceptable for BL [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. Intermediate BL/DLBCL is most commonly observed in adults [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. Among pediatric populations, to date, the English literature only includes reports of one case of intermediate BL/DLBCL in a 2-yr-old Korean boy and eight cases in Chinese children [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Here, we report two additional cases that represent the first report from a western population.</p>
    <sec>
      <title>Case 1</title>
      <p>A 15-yr-old girl with sudden-onset abdominal pain and emesis was found to have a small bowel obstruction and intussusception during a computed tomography (CT) study. An urgent exploratory laparotomy revealed a mass comprising mildly to moderately pleomorphic lymphoid cells that were mostly medium-sized with rare large cells and slightly irregular nuclear contours; these cells primarily contained 2-3 inconspicuous nucleoli or, occasionally, single prominent nucleoli. Mitotic figures were frequent. Focally, tingible body macrophages imparted a "starry sky" appearance. The atypical lymphoid cells were positive for CD20, CD10, BCL-6 (focal, weak), MUM-1, and BCL-2 and negative for terminal deoxynucleotidyl transferase (TdT). The proliferative index, as indicated by Ki-67 staining, was high (&gt;90%; <xref ref-type="fig" rid="F1">Fig. 1</xref>). An Epstein-Barr virus (EBV) study with late membrane protein 1 (LMP1) immunohistochemical stain (IHC) and in situ hybridization for EBV-encoded RNAs (EBER), flow cytometric analysis, and karyotyping were not performed. FISH analysis revealed <italic>MYC</italic> rearrangement but no <italic>BCL2</italic> or <italic>BCL6</italic> rearrangement or copy number changes. Three of the 16 resected lymph nodes were also positive for intermediate BL/DLBCL. The patient underwent chemotherapy with cyclophosphamide, vincristine, prednisone, doxorubicin, and methotrexate. She remained in complete remission 11 months after completing chemotherapy.</p>
    </sec>
    <sec>
      <title>Case 2</title>
      <p>A 4-yr-old boy with a 2-week history of abdominal distension and diarrhea was found to have diffuse bowel wall thickening on CT. A transrectal biopsy revealed a diffuse infiltrate of predominantly medium-sized with rare large atypical lymphoid cells; these cells had slightly irregular nuclear contours, vesicular chromatin, and mostly inconspicuous nucleoli. Apoptotic bodies and mitotic figures were frequently observed. The atypical lymphoid cells were positive for CD20, PAX-5, CD10, BCL-6, and BCL-2 and exhibited a high proliferative index, as indicated by Ki-67 staining (&gt; 95%). MUM-1 staining was negative. The EBV study was negative according to LMP1 IHC and EBER <italic>in situ</italic> hybridization. Concurrent flow cytometric analysis revealed a monoclonal B-cell population with CD19, CD20, CD22, CD10, and surface kappa light-chain expression. The monoclonal B cells were negative for CD5, CD23, CD34, and TdT. A cytogenetic analysis (karyotyping) was not performed. FISH analysis with a <italic>MYC</italic> dual-color break apart probe revealed <italic>MYC</italic> rearrangement. There was no evidence of <italic>BCL2</italic>/<italic>IGH</italic> fusion, <italic>BCL6</italic> rearrangement, or copy number changes in <italic>BCL2</italic> or <italic>BCL6</italic>. The bone marrow and central nervous system were not involved (stage III). This patient received the same chemotherapy regimen as patient 1 and remained in remission for 12 months, as per the last follow-up.</p>
      <p>We conducted a systematic review of the pediatric high-grade mature B-cell lymphoma cases in our archives from 1988 to 2012 and identified 2 cases of intermediate BL/DLBCL. Both cases exhibited histologic morphology compatible with BL but with moderate-to-strong BCL-2 expression. Weak BCL-2 expression might be observed in BL [<xref rid="B2" ref-type="bibr">2</xref>]. In our experience, BCL-2 staining has yielded consistently negative or weakly positive (few cells) results in cases of BL. In addition, Case 1 exhibited focal and weak BCL6 expression and moderate-to-strong MUM-1 expression, which would be unusual for a diagnosis of BL [<xref rid="B2" ref-type="bibr">2</xref>]. The focal and weak BCL6 staining in Case 2 was not likely caused by poor tissue preservation and/or the stain itself, as the staining of samples from the same tissue block for other nuclear markers (MUM-1 and Ki-67) was successful. To the best of our knowledge, these two cases represent the first report of pediatric intermediate BL/DLBCL in a western population. A comparison of the current cases with previously reported pediatric intermediate BL/DLBCL cases in Asian populations is summarized in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
      <p>The current treatments for pediatric BL, DLBCL, and intermediate BL/DLBCL are similar [<xref rid="B8" ref-type="bibr">8</xref>]. However, treatment for patients aged 15-20 yr has been controversial because adolescent DLBCL patients fare better when treated with more aggressive regimens, compared with those who receive a cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like regimen [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. Both of our patients were treated with a BL chemotherapeutic regimen. It will be interesting to observe the responses of our patients, particularly the 15-yr-old female patient, during long-term follow-up. With the development of individualized targeted therapies, the recognition of pediatric intermediate BL/DLBCL might become more clinically relevant.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>No potential conflicts of interest relevant to this article were reported.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carbone</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gloghini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Aiello</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Testi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cabras</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology</article-title>
          <source>Hum Pathol</source>
          <year>2010</year>
          <volume>41</volume>
          <fpage>621</fpage>
          <lpage>631</lpage>
          <pub-id pub-id-type="pmid">20398809</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kluin</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Leoncini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Raphael</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <chapter-title>B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Swerdlow</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Pileri</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Thiele</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vardiman</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <source>WHO classification of tumours of haematopoietic and lymphoid tissues</source>
          <publisher-loc>Lyon</publisher-loc>
          <publisher-name>IARC Press</publisher-name>
          <year>2008</year>
          <fpage>265</fpage>
          <lpage>266</lpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Greffe</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Giller</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>McGranahan</surname>
              <given-names>AN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gray zone lymphomas in pediatric patients</article-title>
          <source>Pediatr Dev Pathol</source>
          <year>2011</year>
          <volume>14</volume>
          <fpage>57</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">20331368</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dickason</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Fayad</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Lennon</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma</article-title>
          <source>Cancer</source>
          <year>2012</year>
          <volume>118</volume>
          <fpage>1566</fpage>
          <lpage>1573</lpage>
          <pub-id pub-id-type="pmid">21882178</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salaverria</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Siebert</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective</article-title>
          <source>J Clin Oncol</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>1835</fpage>
          <lpage>1843</lpage>
          <pub-id pub-id-type="pmid">21482997</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahn</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Seo</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Jeong</surname>
              <given-names>JH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A case of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a Korean child</article-title>
          <source>Ann Lab Med</source>
          <year>2012</year>
          <volume>32</volume>
          <fpage>162</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="pmid">22389885</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Morphological, immunophenotypic and molecular characterization of mature aggressive B-cell lymphomas in Chinese pediatric patients</article-title>
          <source>Leuk Lymphoma</source>
          <year>2011</year>
          <volume>52</volume>
          <fpage>2356</fpage>
          <lpage>2364</lpage>
          <pub-id pub-id-type="pmid">21740296</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reiter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schrappe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Parwaresch</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Henze</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>M&#xFC;ller-Weihrich</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sauter</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-M&#xFC;nster Group</article-title>
          <source>J Clin Oncol</source>
          <year>1995</year>
          <volume>13</volume>
          <fpage>359</fpage>
          <lpage>372</lpage>
          <pub-id pub-id-type="pmid">7844597</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cairo</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Gerrard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sposto</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Auperin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pinkerton</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Michon</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>109</volume>
          <fpage>2736</fpage>
          <lpage>2743</lpage>
          <pub-id pub-id-type="pmid">17138821</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Patte</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Auperin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gerrad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Michon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pinkerton</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sposto</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>109</volume>
          <fpage>2773</fpage>
          <lpage>2780</lpage>
          <pub-id pub-id-type="pmid">17132719</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Morphologic (A, Hematoxylin and eosin staining, &#xD7;50) and immunophenotypic (B-F, &#xD7;20) features of B-cell lymphoma, unclassifiable, with intermediate features between DLBCL and Burkitt lymphoma. (B) CD20, (C) BCL-6, (D) BCL-2, (E) MUM-1, and (F) Ki-67.</p>
      </caption>
      <graphic xlink:href="alm-35-254-g001"/>
    </fig>
    <table-wrap id="T1" orientation="portrait" position="float">
      <label>Table 1</label>
      <caption>
        <p>Comparison of the current cases with previously reported intermediate BL/DLBCL cases in English literature</p>
      </caption>
      <graphic xlink:href="alm-35-254-i001"/>
      <table-wrap-foot>
        <fn>
          <p><sup>*</sup>positive case number/tested case number; <sup>&#x2020;</sup>2 out of 8 cases showed 3 copies of <italic>BCL6</italic>.</p>
          <p>Abbreviations: DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; M, male; F, female; ND, not done; NA, not available; EBER, <italic>in situ</italic> hybridization for Epstein-Barr virus-encoded RNAs.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
